Stay updated on Upadacitinib in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib in Atopic Dermatitis Clinical Trial page.

Latest updates to the Upadacitinib in Atopic Dermatitis Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the upadacitinib atopic dermatitis study is now displayed, including its study design, eligibility criteria, outcome measures, locations, publications, and supporting documents.SummaryDifference100%

- Check15 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check29 days agoChange DetectedAn NIH-wide notice about website terminology changes was added, and the site revision advanced from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden message instead of the study record.SummaryDifference1%

- Check43 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check50 days agoChange DetectedA 403 Forbidden error page is now shown in place of the study record, with the site header/footer visible and a Home link available, indicating restricted access rather than the study details.SummaryDifference0.5%

Stay in the know with updates to Upadacitinib in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib in Atopic Dermatitis Clinical Trial page.